,source,page number,segment number,description,proposed_name,proposed_target,smiles,inchi,inchikey,validation
0,DH-MOTM-Poster-June-2023-Revised.pdf,0,0,"orforglipron
GLP-1R
oral non-peptide GLP-1R agonist
Ph. III for obesity + type 2 diabetes 
from LLC-PK1 cell HTS + opt
N. Engl. J. Med., June 23, 2023
CHUGAI, SHIZUOKA, JP; ELI LILLY, INDIANAPOLIS, IN","orforglipron
GLP-1R
oral non-peptide GLP-1R agonist
Ph. III for obesity + type 2 diabetes 
from LLC-PK1 cell HTS + opt
N. Engl. J. Med., June 23, 2023
CHUGAI, SHIZUOKA, JP; ELI LILLY, INDIANAPOLIS, IN","orforglipron
GLP-1R
oral non-peptide GLP-1R agonist
Ph. III for obesity + type 2 diabetes 
from LLC-PK1 cell HTS + opt
N. Engl. J. Med., June 23, 2023
CHUGAI, SHIZUOKA, JP; ELI LILLY, INDIANAPOLIS, IN",Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F,"InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1",USUWIEBBBWHKNI-KHIFEHGGSA-N,True
1,DH-MOTM-Poster-June-2023-Revised.pdf,0,1,"oral GLP-1-RA full agonist
obesity Ph. IIb, 2.5-120 mg QD, T2D Ph. II, 40-200 mg 
from sensitized cell HTS of 2.8M cmpds + opt.
Press release, June 26, 2023
PFIZER, CAMBRIDGE, MA
danuglipron
GLP-1R","oral GLP-1-RA full agonist
obesity Ph. IIb, 2.5-120 mg QD, T2D Ph. II, 40-200 mg 
from sensitized cell HTS of 2.8M cmpds + opt.
Press release, June 26, 2023
PFIZER, CAMBRIDGE, MA
danuglipron
GLP-1R","oral GLP-1-RA full agonist
obesity Ph. IIb, 2.5-120 mg QD, T2D Ph. II, 40-200 mg 
from sensitized cell HTS of 2.8M cmpds + opt.
Press release, June 26, 2023
PFIZER, CAMBRIDGE, MA
danuglipron
GLP-1R",C1=CC(=NC(=C1)OCC2=CC=C(C=C2F)C#N)C3CCN(CC3)CC4=NC5=C(C=C(C=C5)C(=O)O)N4C[C@@H]6CCO6,"InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1",HYBAKUMPISVZQP-DEOSSOPVSA-N,True
2,DH-MOTM-Poster-June-2023-Revised.pdf,0,2,"vorasidenib  
IDH1/2
oral first-in-class dual IDH1/IDH2 inhibitor
efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD
from SBDD of prior mIDH inhibitor
N. Engl. J. Med., June 4, 2023","vorasidenib  
IDH1/2
oral first-in-class dual IDH1/IDH2 inhibitor
efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD
from SBDD of prior mIDH inhibitor
N. Engl. J. Med., June 4, 2023","vorasidenib  
IDH1/2
oral first-in-class dual IDH1/IDH2 inhibitor
efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD
from SBDD of prior mIDH inhibitor
N. Engl. J. Med., June 4, 2023",C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,"InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1",QCZAWDGAVJMPTA-RNFRBKRXSA-N,True
3,DH-MOTM-Poster-June-2023-Revised.pdf,0,3,"atrasentan
ETAR
oral ETA receptor antagonist
Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome
ligand-based design from prior ETAR antagonists
Acquisition announcement, June 12, 2023
ABBOTT LABS / CHINOOK THERAPEUTICS ","atrasentan
ETAR
oral ETA receptor antagonist
Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome
ligand-based design from prior ETAR antagonists
Acquisition announcement, June 12, 2023
ABBOTT LABS / CHINOOK THERAPEUTICS ","atrasentan
ETAR
oral ETA receptor antagonist
Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome
ligand-based design from prior ETAR antagonists
Acquisition announcement, June 12, 2023
ABBOTT LABS / CHINOOK THERAPEUTICS ",CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,"InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1",MOTJMGVDPWRKOC-QPVYNBJUSA-N,True
4,DH-MOTM-Poster-June-2023-Revised.pdf,0,4,"lirafugratinib
FGFR2
oral covalent FGFR2 inhibitor
Ph. II for cholangiocarcinoma
from rational design with MD simulations
Cancer Discov., June 4, 2023
RELAY THERAPEUTICS INC., CAMBRIDGE, MA","lirafugratinib
FGFR2
oral covalent FGFR2 inhibitor
Ph. II for cholangiocarcinoma
from rational design with MD simulations
Cancer Discov., June 4, 2023
RELAY THERAPEUTICS INC., CAMBRIDGE, MA","lirafugratinib
FGFR2
oral covalent FGFR2 inhibitor
Ph. II for cholangiocarcinoma
from rational design with MD simulations
Cancer Discov., June 4, 2023
RELAY THERAPEUTICS INC., CAMBRIDGE, MA",C=C(C)C(=O)Nc1ccc(-c2c(-c3ccc(Oc4nccc(C)n4)c(F)c3)c3c(N)ncnc3n2C)cc1,"InChI=1S/C28H24FN7O2/c1-15(2)27(37)35-19-8-5-17(6-9-19)24-22(23-25(30)32-14-33-26(23)36(24)4)18-7-10-21(20(29)13-18)38-28-31-12-11-16(3)34-28/h5-14H,1H2,2-4H3,(H,35,37)(H2,30,32,33)",XOQVZSSDIQQUGO-UHFFFAOYSA-N,True
5,DH-MOTM-Poster-June-2023-Revised.pdf,0,5,"PCO371
PTH1R
oral PTH1R agonist
preclinical for parathyroid hormone disorders
functional screen vs. cells expressing hPTHR1 
Nature, June 7, 2023
CHUGAI, SHIZUOKA, JP ","PCO371
PTH1R
oral PTH1R agonist
preclinical for parathyroid hormone disorders
functional screen vs. cells expressing hPTHR1 
Nature, June 7, 2023
CHUGAI, SHIZUOKA, JP ","PCO371
PTH1R
oral PTH1R agonist
preclinical for parathyroid hormone disorders
functional screen vs. cells expressing hPTHR1 
Nature, June 7, 2023
CHUGAI, SHIZUOKA, JP ",Cc1cc(N2C(=O)NC(=O)C2(C)C)cc(C)c1CCS(=O)(=O)N1CCC2(CC1)N=C(c1ccc(OC(F)(F)F)cc1)NC2=O,"InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)",LDZJFVOUPUFOHX-UHFFFAOYSA-N,True
6,DH-MOTM-Poster-June-2023-Revised.pdf,0,6,"GNE-7883
pan-TEAD
pan-TEAD inhibitor 
preclinical efficacy in xenograft models
from TEAD3-YAP HTS of >2M cmpds + opt.
Nature, June 5, 2023
GENENTECH, SOUTH SAN FRANCISCO, CA ","GNE-7883
pan-TEAD
pan-TEAD inhibitor 
preclinical efficacy in xenograft models
from TEAD3-YAP HTS of >2M cmpds + opt.
Nature, June 5, 2023
GENENTECH, SOUTH SAN FRANCISCO, CA ","GNE-7883
pan-TEAD
pan-TEAD inhibitor 
preclinical efficacy in xenograft models
from TEAD3-YAP HTS of >2M cmpds + opt.
Nature, June 5, 2023
GENENTECH, SOUTH SAN FRANCISCO, CA ",Cc1nccnc1-c1nn2c(=O)cc(-c3ccc(C4CCCCC4)cc3)[nH]c2c1C(=O)N1CC(CF)C1,"InChI=1S/C28H29FN6O2/c1-17-25(31-12-11-30-17)26-24(28(37)34-15-18(14-29)16-34)27-32-22(13-23(36)35(27)33-26)21-9-7-20(8-10-21)19-5-3-2-4-6-19/h7-13,18-19,32H,2-6,14-16H2,1H3",UNRTVIQQMJRQLZ-UHFFFAOYSA-N,False
7,DH-MOTM-Poster-June-2023-Revised.pdf,0,7,"compound 13
DCAF1 ligand
DCAF1 binder 
preclinical, applied to targeted protein 
degradation
from HTS + optimization
ACS Med. Chem. Lett. June 2, 2023
NOVARTIS, BASEL, CH ","compound 13
DCAF1 ligand
DCAF1 binder 
preclinical, applied to targeted protein 
degradation
from HTS + optimization
ACS Med. Chem. Lett. June 2, 2023
NOVARTIS, BASEL, CH ","compound 13
DCAF1 ligand
DCAF1 binder 
preclinical, applied to targeted protein 
degradation
from HTS + optimization
ACS Med. Chem. Lett. June 2, 2023
NOVARTIS, BASEL, CH ",CC.CC(=O)N1CCN(c2ccc3c(NCCN)nc(C4(c5ccc(Cl)cc5)CCCCC4)nc3c2)CC1,"InChI=1S/C28H35ClN6O.C2H6/c1-20(36)34-15-17-35(18-16-34)23-9-10-24-25(19-23)32-27(33-26(24)31-14-13-30)28(11-3-2-4-12-28)21-5-7-22(29)8-6-21;1-2/h5-10,19H,2-4,11-18,30H2,1H3,(H,31,32,33);1-2H3",YWOUFXHMFCLPRT-UHFFFAOYSA-N,False
8,DH-MOTM-Poster-June-2023-Revised.pdf,0,8,"CT3 
topoisomerase II
irreversible trypanosomal topo. II inhibitor 
efficacy in Chagas and sleeping sickness models
from phenotypic screen against trypanosomes
Science, June 29, 2023
NOVARTIS (NITD), EMERYVILLE, CA / SINGAPORE ","CT3 
topoisomerase II
irreversible trypanosomal topo. II inhibitor 
efficacy in Chagas and sleeping sickness models
from phenotypic screen against trypanosomes
Science, June 29, 2023
NOVARTIS (NITD), EMERYVILLE, CA / SINGAPORE ","CT3 
topoisomerase II
irreversible trypanosomal topo. II inhibitor 
efficacy in Chagas and sleeping sickness models
from phenotypic screen against trypanosomes
Science, June 29, 2023
NOVARTIS (NITD), EMERYVILLE, CA / SINGAPORE ",N#Cc1ncn(CC(=O)N2Cc3ccc(-c4cc(F)cnc4C(F)(F)F)cc3C2)n1,"InChI=1S/C19H12F4N6O/c20-14-4-15(18(25-6-14)19(21,22)23)11-1-2-12-7-28(8-13(12)3-11)17(30)9-29-10-26-16(5-24)27-29/h1-4,6,10H,7-9H2",JDTWUDDOSHJEIZ-UHFFFAOYSA-N,True
